Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350828 | 0.91 | CA2 (0.45) | GPR84CA2FDPSCA1 | |
| SCHEMBL2348617 | 0.89 | GPR84 (0.47) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2341254 | 0.88 | GPR84 (0.45) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2346027 | 0.88 | CA2 (0.47) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL14761700 | 0.83 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL16050313 | 0.80 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL20746347 | 0.79 | CA1 (0.50) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17474425 | 0.79 | CA2 (0.46) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2349609 | 0.78 | CA2 (0.40) | GPR84FFAR1CA2FDPSCA1 | |
| SCHEMBL268638 | 0.77 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078724-B1 | PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES | ASAHI CHEMICAL IND (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8008518-B2 | Process for producing dialkyl tin dialkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100041908-A1 | PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2078724-A1 | PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES | Asahi Kasei Chemicals Corporation (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041908-A1 | PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES | DEK, DDT, DERA | GPR84 3869/4885FFAR1 2261/4885MAPT 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.